Genmab — August 2019
-
Bulder: can you read Nordea comments from 22 August?
-
Nordea write: patients had failed 4 or more prior lines of therapy including platinum based chemo
-
So infact EnaV is 5th line...
-
-
Bergenbio: Cohort A will consist of patients who received a maximum of 1 prior line of platinum-containing chemotherapy and no prior immunotherapy of any kind. Cohort B will consist of patients with a maximum of 2 prior lines whereas the most recent line must have included a PD-(L)1 inhibitor.
-
-
Man skal nok mere bekymre sig om Daiichi Sankyo´s TROP2 ADC - noget tyder på at de har knækket koden med ADC således, at de i hvert fald kan opnå god effekt. De mangler måske stadig et bedre terapeutisk vindue, så de også kan slippe af med bivirkningerne
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind